Unity Bancorp, Inc. (UNTY)
NASDAQ: UNTY · Real-Time Price · USD
47.13
+0.65 (1.40%)
At close: Aug 8, 2025, 4:00 PM
47.54
+0.41 (0.87%)
After-hours: Aug 8, 2025, 5:57 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $56, which forecasts a 18.82% increase in the stock price over the next year. The lowest target is $50 and the highest is $63.
Price Target: $56 (+18.82%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Buy Maintains $55 → $63 | Buy | Maintains | $55 → $63 | +33.67% | Jul 18, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $54 → $50 | Buy | Maintains | $54 → $50 | +6.09% | Apr 14, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Buy Reiterates $51 → $55 | Buy | Reiterates | $51 → $55 | +16.70% | Jan 16, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $53 → $54 | Buy | Reiterates | $53 → $54 | +14.58% | Jan 16, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Buy Maintains $43 → $51 | Buy | Maintains | $43 → $51 | +8.21% | Dec 4, 2024 |
Financial Forecast
Revenue This Year
126.40M
from 103.13M
Increased by 22.56%
Revenue Next Year
139.20M
from 126.40M
Increased by 10.13%
EPS This Year
4.95
from 4.06
Increased by 21.97%
EPS Next Year
5.61
from 4.95
Increased by 13.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 130.4M | 144.3M |
| Avg | 126.4M | 139.2M |
| Low | 121.2M | 132.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 26.4% | 14.1% |
| Avg | 22.6% | 10.1% |
| Low | 17.5% | 5.1% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 5.18 | 6.01 |
| Avg | 4.95 | 5.61 |
| Low | 4.68 | 5.08 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | 27.6% | 21.3% |
| Avg | 22.0% | 13.3% |
| Low | 15.4% | 2.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.